Paloma Satorres-Martinez

Dr. Paloma Satorres-Martinez


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2023 in Epidemiologia
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
OGOlga Guerra-Murcia
Olga Guerra-Murcia
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
AOAlejandro Orrico-Sánchez
Alejandro Orrico-Sánchez
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Our objective was to estimate the incidence of COVID-19 and the ABO blood Groups in the mass-gathering events (MGEs) during the Falles Festival in Borriana (Spain) from 6–10 March 2020. We conducted a population-based retrospective cohort study and measured anti-SARS-CoV-2 antibodies and the ABO of participants. We performed laboratory COVID-19 tests and obtained the ABO in 775 subjects (72.8% of the original exposed cohort): O-group (45.2%), A-group (43.1%), B-group (8.5%) and AB-group (3.4%). Adjusted for confounding factors, including COVID-19 exposure during the MGEs, attack rates of COVID-19 for each ABO group were 55.4%, 59.6%, 60.2%, and 63.7%. The adjusted relative risks were for O-group 0.93 (95% Confidence Interval [CI] 0.83–1.04), for A-group 1.06 (95% CI 0.94–1.18), for B-group 1.04 (95%CI 0.88–1.24), and for AB-group 1.11 (95% CI 0.81–1.51) with no significant differences. Conclusions: Our results suggest no effect of ABO on COVID-19 incidence. We observed weak but not significant protection of the O-group and not a significantly greater infection risk for the remaining groups compared with the O-group. More studies are needed to resolve the controversies regarding the association between ABO and COVID-19.

10 April 2024 in Epidemiologia
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
AOAlejandro Orrico-Sánchez
Alejandro Orrico-Sánchez
LLLORNA GOMEZ LANAS
LORNA GOMEZ LANAS
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Our goal was to determine the cellular immune response (CIR) in a sample of the Borriana COVID-19 cohort (Spain) to identify associated factors and their relationship with infection, reinfection and sequelae. We conducted a nested case–control study using a randomly selected sample of 225 individuals aged 18 and older, including 36 individuals naïve to the SARS-CoV-2 infection and 189 infected patients. We employed flow-cytometry–based immunoassays for intracellular cytokine staining, using Wuhan and BA.2 antigens, and chemiluminescence microparticle immunoassay to detect SARS-CoV-2 antibodies. Logistic regression models were applied. A total of 215 (95.6%) participants exhibited T-cell response (TCR) to at least one antigen. Positive responses of CD4+ and CD8+ T cells were 89.8% and 85.3%, respectively. No difference in CIR was found between naïve and infected patients. Patients who experienced sequelae exhibited a higher CIR than those without. A positive correlation was observed between TCR and anti-spike IgG levels. Factors positively associated with the TCR included blood group A, number of SARS-CoV-2 vaccine doses received, and anti-N IgM; factors inversely related were the time elapsed since the last vaccine dose or infection, and blood group B. These findings contribute valuable insights into the nuanced immune landscape shaped by SARS-CoV-2 infection and vaccination.

Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
LLLaura López-Diago
Laura López-Diago
IGIsabel Aleixandre Górriz
Isabel Aleixandre Górriz
OPOscar Pérez-Olaso
Oscar Pérez-Olaso
DTDIEGO SALA TRULL
DIEGO SALA TRULL
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
A deficient vitamin D (VitD) status has been associated with SARS-CoV-2 infections, severity, and mortality. However, this status related to SARS-CoV-2 reinfections has been studied little. Our aim was to quantify the risk of reinfections considering VitD status before reinfection. Methods: We performed a population-based prospective cohort study in Borriana (Valencia Community, Spain) during 2020–2023, measuring 25-hydroxyvitamin D [25(OH)D] levels by electrochemiluminescence. Cox proportional hazards models were employed. Results: Of a total of 644 SARS-CoV-2 cases with confirmed laboratory tests, 378 (58.9%) were included in our study, with an average age of 38.8 years; 241 were females (63.8%), and 127 reinfections occurred (33.6%). SARS-CoV-2 reinfection incidence rates per 1000 person-days by VitD status were 0.50 for a deficient status (<20 ng/mL), 0.50 for an insufficient status (20–29 ng/mL), and 0.37 for a sufficient status (≥30 ng/mL). Compared with a sufficient VitD status, adjusted hazard ratios were 1.79 (95% confidence interval [CI] 0.89–3.59) for a deficient status and 1.59 (95% CI 1.06–2.38) for an insufficient status with a significant inverse dose–response (p = 0.02). These results can help improve nutritional actions against SARS-CoV-2 reinfections. Conclusions: These results suggest that a VitD status lower than 30 ng/mL showed a higher risk of SARS-CoV-2 reinfection. Achieving and maintaining a sufficient VitD status is recommended to prevent reinfections.

19 December 2025 in Epidemiologia
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
OPOscar Pérez-Olaso
Oscar Pérez-Olaso
DTDIEGO SALA TRULL
DIEGO SALA TRULL
ARAlba Del Río
Alba Del Río
LLLaura López-Diago
Laura López-Diago
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Background and Objective: Evaluating vaccine effectiveness (VE) is essential to implementing prevention strategies, and our objective was to estimate the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines in preventing SARS-CoV-2 infection. Materials and Methods: We carried out a population-based, prospective cohort study on the Borriana COVID-19 cohort (Valencia Community, Spain) during the 2021–2023 period, considering all SARS-CoV-2 cases that occurred after the SARS-CoV-2 vaccine campaign started in January 2021 (first approach), as well as only symptomatic cases (second approach). Multivariable robust Poisson regression models were employed. Results: In this cohort with 301 participants, 285 were vaccinated, among whom 228 received only SARS-CoV-2 mRNA vaccines, and 57 received mRNA vaccines and other vaccines. In the first approach, there were 226 cases and 75 non-cases. The adjusted VE for three doses of vaccine was 37% (95% confidence interval [CI]: 22–49%) to prevent infection. In the second approach, with 153 symptomatic cases after excluding 73 asymptomatic cases, the adjusted VE for three doses of vaccine was 50% (95% CI 33–63%) to prevent symptomatic infection. Three doses of vaccine exhibited modest but significant protection against infection and symptomatic infection. Conclusions: This study recommends surveilling SARS-CoV-2 infections and variants, vaccinating at-risk populations, and developing new vaccines.

9 August 2024 in Epidemiologia
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
DTDIEGO SALA TRULL
DIEGO SALA TRULL
ARAlba Del Río
Alba Del Río
Manuel Sánchez-UrbanoManuel Sánchez-Urbano
Manuel Sánchez-Urbano
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Determining the number of cases of an epidemic is the first function of epidemiological surveillance. An important underreporting of cases was observed in many locations during the first wave of the COVID-19 pandemic. To estimate this underreporting in the COVID-19 outbreak of Borriana (Valencia Community, Spain) in March 2020, a cross-sectional study was performed in June 2020 querying the public health register. Logistic regression models were used. Of a total of 468 symptomatic COVID-19 cases diagnosed in the outbreak through anti-SARS-CoV-2 serology, 36 cases were reported (7.7%), resulting in an underreporting proportion of 92.3% (95% confidence interval [CI], 89.5–94.6%), with 13 unreported cases for every reported case. Only positive SARS-CoV-2 polymerase chain reaction cases were predominantly reported due to a limited testing capacity and following a national protocol. Significant factors associated with underreporting included no medical assistance for COVID-19 disease, with an adjusted odds ratio [aOR] of 10.83 (95% CI 2.49–47.11); no chronic illness, aOR = 2.81 (95% CI 1.28–6.17); middle and lower social classes, aOR = 3.12 (95% CI 1.42–6.85); younger age, aOR = 0.97 (95% CI 0.94–0.99); and a shorter duration of illness, aOR = 0.98 (95% CI 0.97–0.99). To improve the surveillance of future epidemics, new approaches are recommended.

16 April 2026 in COVID
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
OPOscar Pérez-Olaso
Oscar Pérez-Olaso
DTDIEGO SALA TRULL
DIEGO SALA TRULL
PSPaloma Satorres-Martinez
Paloma Satorres-Martinez
LLLaura López-Diago
Laura López-Diago
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Background and Objective: After SARS-CoV-2 infection, Long COVID (LC) syndrome has occurred in a high proportion of patients, affecting their health. The aim of this study was to estimate the incidence of LC, as well as its risk and protective factors. Materials and Methods: We conducted a prospective population-based cohort study of the Borriana COVID-19 cohort (Castellon Province, Valencia Community, Spain) from May 2020 to August 2023, with a follow-up of 40 months, using the LC definition given by the World Health Organization. Inverse probability-weighted regression adjustment was applied in the statistical analysis. Results: With a participation rate of 63.8% and a total of 722 participants, the mean age was 37.7 ± 17.4 years, and 460 (62.3%) were female. Among them, 644 had experienced a SARS-CoV-2 infection, and 184 developed LC, corresponding to a cumulative incidence of 28.6%. At the time of follow-up, 135 patients remained affected by LC, and one LC-related death was recorded. Significant risk factors for LC included older age, female sex, being part of a small family, having a chronic disease, SARS-CoV-2 exposure, and disease severity. Asymptomatic COVID-19 infection and SARS-CoV-2 vaccination were significantly protective factors. Conclusions: A substantial incidence of LC was observed, along with a low recovery rate. Several risk and protective factors were identified. Continued follow-up of this cohort, improved medical care for patients with non-recovered LC, ongoing surveillance of SARS-CoV-2 infections, and vaccination of the at-risk populations against SARS-CoV-2 are recommended.